Texas
LATEST FROM BIOSPACE
Shares of Reata Pharmaceuticals have plunged nearly 40% in premarket trading after an FDA advisory panel recommended against the approval of its Alport syndrome disease treatment, bardoxolone.
Austin, Texas-based Aeglea Biotherapeutics reported what initially appears to be positive outcomes for its Phase III PEACE trial of pegzilarginase in Arginase 1 Deficiency (ARG1-D).
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The U.S. Securities and Exchange Commission has launched an investigation into Texas-based Cassava Sciences.
Investors are falling in with these biotech companies, dropping dollars to fuel their work for the latest advancement in life sciences.
Houston-based money manager Alan Eisenman testified in the ongoing Elizabeth Holmes fraud trial that he sought “straight answers” about the company’s work for several years.
Vaxxinity set its initial public offering price at $13 per share, raising $76 million. The company was launched in April via consolidation of the vaccine development efforts of COVAXX and United Neuroscience.
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
PRESS RELEASES